Erenumab escalation in migraine - double dose without additional benefit - a retrospective experience.

Autor: Heintz S; Department of Neurology, University Hospital Halle, Martin Luther University Halle- Wittenberg, Wittenberg, Germany., Storch P; Headache Center Jena, Department of Neurology, University Hospital Jena, Jena, Germany., Burow P; Department of Neurology, University Hospital Halle, Martin Luther University Halle- Wittenberg, Wittenberg, Germany., Maier P; Department of Neurology, University Hospital Halle, Martin Luther University Halle- Wittenberg, Wittenberg, Germany., Obermann M; Department of Neurology, Klinikum Weser-Egge, Höxter, Germany., Stoessel G; Headache Center Jena, Department of Neurology, University Hospital Jena, Jena, Germany., Kraya T; Department of Neurology, University Hospital Halle, Martin Luther University Halle- Wittenberg, Wittenberg, Germany.; Department of Neurology, Hospital St. Georg, Leipzig, Germany., Naegel S; Department of Neurology, University Hospital Halle, Martin Luther University Halle- Wittenberg, Wittenberg, Germany. steffen.naegel@medizin.uni-halle.de.; Department of Neurology, Alfried Krupp Krankenhaus Essen, Alfried-Krupp-Straße 21, 45131, Essen, Germany. steffen.naegel@medizin.uni-halle.de.
Jazyk: angličtina
Zdroj: Acta neurologica Belgica [Acta Neurol Belg] 2024 Oct; Vol. 124 (5), pp. 1663-1670. Date of Electronic Publication: 2024 Jul 27.
DOI: 10.1007/s13760-024-02603-z
Abstrakt: Background: Erenumab is a monoclonal antibody specifically targeting the CGRP-receptor. Several studies showed efficacy and safety in patients with migraine. Less is known regarding dosage increase, especially in a difficult to treat patients. The aim of the study is to evaluate the increased dosage under real world conditions with particular focus on 70 mg non-responders.
Methods: In a retrospective analysis, patients treated in tertiary headache centers (Halle or Jena, Germany) receiving 70 mg erenumab for at least 3 months with a dosage increase to 140 mg were analyzed. Data were evaluated regarding headache days, intake of acute medication, previous prophylaxis, and medication overuse. Baseline and all treatment intervals were determined as three-month periods.
Results: Datasets of 52 migraine patients (90.4% women) aged between 22 and 78 years (mean 50.4 years, SD 12.1 years) were analyzed. At baseline (mean headache-days 15.67 ± 6.37) 51.9% met criteria for chronic migraine and 56% were currently overusing acute medication. While therapy with 70 mg showed significant improvement in headache days and 50% response, further improvement was not achieved for therapy escalation to 140 mg. The same applies to the secondary endpoints and covers the entire study population as well as the subgroups of chronic and episodic migraine. The 50% response of the 70 mg non-responders for escalation was only 5.14%.
Conclusions: In this difficult-to-treat patient cohort we reconfirmed the effectiveness of erenumab, but could not detect any additional benefit for a dosage escalation from 70 mg to 140 mg erenumab.
Competing Interests: Declarations: PS, PB, TK and SN received lecture fees from Novartis. PS and SN were also provided with a research grant from Novartis.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: